Pyxis Oncology (PYXS) Other Non Operating Income (2021)
Pyxis Oncology (PYXS) posted quarterly Other Non Operating Income of -$410000.0 for Q4 2021, up 83.98% quarter-over-quarter from -$2.6 million in Q3 2021.
Pyxis Oncology (PYXS) Other Non Operating Income (2021) Analysis & Trends
Pyxis Oncology (PYXS) has reported Other Non Operating Income for 1 consecutive years, with -$410000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Other Non Operating Income changed N/A year-over-year to -$410000.0; the TTM figure through Dec 2021 stood at -$6.2 million (changed N/A YoY), while the FY2021 annual figure was -$6.2 million, changed N/A from the prior year.
- Other Non Operating Income advanced to -$410000.0 in Q4 2021 per PYXS's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at -$410000.0 in Q4 2021 and bottomed at -$2.6 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -410,000.00 |
| Sep 30, 2021 | -2.56 Mn |
| Jun 30, 2021 | -2.16 Mn |
| Mar 31, 2021 | -1.10 Mn |